What is the most recent earnings date for PRLD stock?
PRELUDE THERAPEUTICS INC (PRLD) last reported earnings on 3/10/2026.
NASDAQ:PRLD • US74065P1012
Past quarterly earnings results for PRELUDE THERAPEUTICS INC (PRLD), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.20 | -0.03 | -576.13% | 47.37% | 5.64M | 35.7M | -84.20% | 41.00% |
| Q3 2025 | -0.26 | -0.37 | 30.21% | 39.53% | 6.5M | - | 116.67% | |
| Q2 2025 | -0.41 | -0.45 | 8.54% | 10.87% | - | - | ||
| Q1 2025 | -0.42 | -0.48 | 12.08% | - | - | - | ||
| Q4 2024 | -0.38 | -0.47 | 19.59% | 17.39% | 4M | - | - | |
| Q3 2024 | -0.43 | -0.48 | 10.65% | 4.44% | 3M | - | - | |
| Q2 2024 | -0.46 | -0.44 | -4.88% | 14.81% | - | - | ||
| Q1 2024 | -0.42 | -0.49 | 15.10% | 27.59% | - | - | ||
| Q4 2023 | -0.46 | -0.50 | 7.96% | 23.33% | - | - | ||
| Q3 2023 | -0.45 | -0.59 | 24.24% | 28.57% | - | - | ||
| Q2 2023 | -0.54 | -0.65 | 16.41% | 6.90% | - | - | ||
| Q1 2023 | -0.58 | -0.70 | 16.99% | 7.94% | - | - | ||
| Q4 2022 | -0.60 | -0.64 | 6.33% | 15.49% | - | - | ||
| Q3 2022 | -0.63 | -0.65 | 2.89% | 4.55% | - | - | ||
| Q2 2022 | -0.58 | -0.62 | 6.78% | - | - | - | ||
| Q1 2022 | -0.63 | -0.66 | 4.98% | -34.04% | - | - | ||
| Q4 2021 | -0.71 | -0.70 | -1.99% | -57.78% | - | - | ||
| Q3 2021 | -0.66 | -0.64 | -3.53% | 87.43% | - | - | ||
| Q2 2021 | -0.58 | -0.50 | -15.11% | - | - | - | ||
| Q1 2021 | -0.47 | -0.43 | -8.68% | - | - | - | ||
| Q4 2020 | -0.45 | -0.48 | 5.63% | - | - | - | ||
| Q3 2020 | -5.25 | -0.44 | -1,096.99% | - | - | - | ||
| Q2 2020 | - | - | - | - |
Notes
PRELUDE THERAPEUTICS INC (PRLD) last reported earnings on 3/10/2026.
PRELUDE THERAPEUTICS INC (PRLD) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, PRELUDE THERAPEUTICS INC (PRLD) has beaten EPS estimates in 3 out of 4 releases.